These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 22033326)

  • 1. p53 Regulates insulin-like growth factor-I receptor gene expression in uterine serous carcinoma and predicts responsiveness to an insulin-like growth factor-I receptor-directed targeted therapy.
    Attias-Geva Z; Bentov I; Kidron D; Amichay K; Sarfstein R; Fishman A; Bruchim I; Werner H
    Eur J Cancer; 2012 Jul; 48(10):1570-80. PubMed ID: 22033326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Caveolin-1 up-regulates IGF-I receptor gene transcription in breast cancer cells via Sp1- and p53-dependent pathways.
    Glait C; Tencer L; Ravid D; Sarfstein R; Liscovitch M; Werner H
    Exp Cell Res; 2006 Nov; 312(19):3899-908. PubMed ID: 17014845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen receptor regulates insulin-like growth factor-I receptor gene expression in breast tumor cells: involvement of transcription factor Sp1.
    Maor S; Mayer D; Yarden RI; Lee AV; Sarfstein R; Werner H; Papa MZ
    J Endocrinol; 2006 Dec; 191(3):605-12. PubMed ID: 17170218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repression of the insulin receptor promoter by the tumor suppressor gene product p53: a possible mechanism for receptor overexpression in breast cancer.
    Webster NJ; Resnik JL; Reichart DB; Strauss B; Haas M; Seely BL
    Cancer Res; 1996 Jun; 56(12):2781-8. PubMed ID: 8665514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA1 is expressed in uterine serous carcinoma (USC) and controls insulin-like growth factor I receptor (IGF-IR) gene expression in USC cell lines.
    Amichay K; Kidron D; Attias-Geva Z; Schayek H; Sarfstein R; Fishman A; Werner H; Bruchim I
    Int J Gynecol Cancer; 2012 Jun; 22(5):748-54. PubMed ID: 22635027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcriptional activation of the insulin-like growth factor I receptor gene by the Kruppel-like factor 6 (KLF6) tumor suppressor protein: potential interactions between KLF6 and p53.
    Rubinstein M; Idelman G; Plymate SR; Narla G; Friedman SL; Werner H
    Endocrinology; 2004 Aug; 145(8):3769-77. PubMed ID: 15131018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcription factor E2F1 is a potent transactivator of the insulin-like growth factor-I receptor (IGF-IR) gene.
    Schayek H; Bentov I; Rotem I; Pasmanik-Chor M; Ginsberg D; Plymate SR; Werner H
    Growth Horm IGF Res; 2010 Feb; 20(1):68-72. PubMed ID: 19703789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional and physical interactions between BRCA1 and p53 in transcriptional regulation of the IGF-IR gene.
    Abramovitch S; Werner H
    Horm Metab Res; 2003; 35(11-12):758-62. PubMed ID: 14710355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metformin downregulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent manners.
    Sarfstein R; Friedman Y; Attias-Geva Z; Fishman A; Bruchim I; Werner H
    PLoS One; 2013; 8(4):e61537. PubMed ID: 23620761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcriptional regulation of the insulin-like growth factor-I receptor gene in breast cancer.
    Sarfstein R; Maor S; Reizner N; Abramovitch S; Werner H
    Mol Cell Endocrinol; 2006 Jun; 252(1-2):241-6. PubMed ID: 16647191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin-like growth factor-I receptor inhibition by specific tyrosine kinase inhibitor NVP-AEW541 in endometrioid and serous papillary endometrial cancer cell lines.
    Attias-Geva Z; Bentov I; Fishman A; Werner H; Bruchim I
    Gynecol Oncol; 2011 May; 121(2):383-9. PubMed ID: 21295335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The insulin-like growth factor-I receptor gene: a downstream target for oncogene and tumor suppressor action.
    Werner H; Maor S
    Trends Endocrinol Metab; 2006 Aug; 17(6):236-42. PubMed ID: 16815029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma.
    Chiesa-Vottero AG; Malpica A; Deavers MT; Broaddus R; Nuovo GJ; Silva EG
    Int J Gynecol Pathol; 2007 Jul; 26(3):328-33. PubMed ID: 17581420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin-like growth factor-I receptor (IGF-IR) targeting with monoclonal antibody cixutumumab (IMC-A12) inhibits IGF-I action in endometrial cancer cells.
    Attias-Geva Z; Bentov I; Ludwig DL; Fishman A; Bruchim I; Werner H
    Eur J Cancer; 2011 Jul; 47(11):1717-26. PubMed ID: 21450456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interplay of insulin-like growth factor-II, insulin-like growth factor-I, insulin-like growth factor-I receptor, COX-2, and matrix metalloproteinase-7, play key roles in the early stage of colorectal carcinogenesis.
    Nosho K; Yamamoto H; Taniguchi H; Adachi Y; Yoshida Y; Arimura Y; Endo T; Hinoda Y; Imai K
    Clin Cancer Res; 2004 Dec; 10(23):7950-7. PubMed ID: 15585629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 regulates insulin-like growth factor-I (IGF-I) receptor expression and IGF-I-induced tyrosine phosphorylation in an osteosarcoma cell line: interaction between p53 and Sp1.
    Ohlsson C; Kley N; Werner H; LeRoith D
    Endocrinology; 1998 Mar; 139(3):1101-7. PubMed ID: 9492043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis.
    Kumar-Singh S; Segers K; Rodeck U; Backhovens H; Bogers J; Weyler J; Van Broeckhoven C; Van Marck E
    J Pathol; 1997 Jan; 181(1):67-74. PubMed ID: 9072005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model.
    Huang F; Hurlburt W; Greer A; Reeves KA; Hillerman S; Chang H; Fargnoli J; Graf Finckenstein F; Gottardis MM; Carboni JM
    Cancer Res; 2010 Sep; 70(18):7221-31. PubMed ID: 20807811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin-like growth factor receptor expression is associated with aggressive phenotypes and has therapeutic activity in biliary tract cancers.
    Ohashi H; Adachi Y; Yamamoto H; Taniguchi H; Nosho K; Suzuki H; Arimura Y; Imai K; Carbone DP; Shinomura Y
    Cancer Sci; 2012 Feb; 103(2):252-61. PubMed ID: 22044563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated insulin-like growth factor-I receptor (IGF-IR) levels in primary breast tumors associated with BRCA1 mutations.
    Maor S; Yosepovich A; Papa MZ; Yarden RI; Mayer D; Friedman E; Werner H
    Cancer Lett; 2007 Nov; 257(2):236-43. PubMed ID: 17766039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.